Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc announced the results of its Annual General Meeting held on June 30, 2021, where all resolutions were passed. The company, known for its innovative liquid biopsy technology, is progressing with the Parsortix system, which has received CE Mark approval in Europe and is awaiting FDA clearance in the U.S. for metastatic breast cancer applications. ANGLE's ongoing clinical studies show promising results, including a recent ovarian cancer test with an accuracy rate of 95.1%. Their technology aims to enhance cancer diagnostics through non-invasive methods.
ANGLE plc (AIM:AGL OTCQX:ANPCY) announces its Annual General Meeting (AGM) will take place on June 30, 2021, at 2:00 PM in Guildford, UK, as a closed meeting due to COVID-19 restrictions. Only two shareholders are required for a quorum, with executive members attending in person and others remotely. Voting will be online via proxy, and shareholders must register in advance to attend online. A business update will follow the AGM, and questions can be submitted to the Board in advance. The Annual Report was distributed to shareholders on June 4, 2021.
ANGLE plc has announced a pivotal study revealing significant differences in EGFR mutations between circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. Conducted by a research team from the University of Athens, this study highlights the importance of analyzing CTCs for better treatment decisions. The results indicate CTCs can provide real-time insights into tumor evolution and resistance, unlike ctDNA, which offers historical data. This research underscores the potential of liquid biopsies in safer, cost-effective monitoring of cancer progression.
ANGLE plc (OTCQX:ANPCY) has confirmed the completion of its response to the FDA's Additional Information Request regarding the Parsortix system, a liquid biopsy technology. The comprehensive response has been submitted as planned, and the company expects a regulatory decision during H2 2021. The Parsortix system aims to become the first FDA-cleared device for harvesting circulating tumor cells (CTCs), enhancing cancer diagnostics. The De Novo process entails inherent uncertainties regarding timing and success, yet ANGLE remains optimistic about the FDA's review outcome.
ANGLE plc announces promising research from Washington University School of Medicine demonstrating the effectiveness of the Parsortix system in isolating rare cancer cells from breast cancer patients' bone marrow. This breakthrough could enhance the identification of biomarkers, leading to targeted treatments that may prevent relapse in patients in remission. With breast cancer affecting 3.7 million women in the US, the research indicates Parsortix's potential to eradicate dormant Disseminated Tumor Cells (DTCs) and improve patient outcomes.
Summary not available.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced the issuance of 216,000 new Ordinary shares following the exercise of employee options. These shares will rank equally with existing shares. An application for their trading admission on AIM has been submitted, with trading anticipated to begin on 24 May 2021. Post-admission, the total number of Ordinary Shares will stand at 215,867,845. The company continues to develop its liquid biopsy technology, particularly the Parsortix system, which has shown promise in clinical studies for cancer diagnostics.
ANGLE plc (OTCQX:ANPCY) announced significant advancements from a study conducted by the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, focusing on triple negative breast cancer (TNBC). The study utilized ANGLE's Parsortix system to isolate circulating tumor cells (CTCs) concurrently with circulating tumor DNA (ctDNA) from a single blood sample. This method revealed multiple druggable targets associated with 12 FDA-approved treatment options. This research highlights the potential for non-invasive monitoring and precision therapy in TNBC, which is known for its limited treatment options and aggressive nature.
ANGLE plc (AIM: AGL OTCQX: ANPCY) has issued 203,333 new Ordinary shares following the exercise of employee options. The shares, valued at £0.10 each, will rank pari passu with existing shares. Admission to trading on AIM is expected to commence on 7 May 2021, increasing the total number of Ordinary Shares to 215,651,845. The company is known for its liquid biopsy technology, particularly its Parsortix system, which aims to transform cancer diagnostics and monitoring.
ANGLE plc has reported its preliminary results for the year ending December 31, 2020, highlighting significant operational and financial developments. The company made a full De Novo FDA submission for the Parsortix system aimed at capturing circulating tumor cells. Key achievements include the completion of patient enrollment for an ovarian cancer study and the signing of a large-scale contract with a pharmaceutical customer, potentially generating up to US$1.2 million in revenue. Financially, revenue increased to £0.8 million, while losses rose to £11.6 million.